Marshall Wace’s Verona Pharma VRNA Stock Holding History

Marshall Wace’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-147,768	Closed	-$15.8M	–	3521
2025 Q3	$15.8M	Buy	147,768 +121,418	+461%	+$12.7M	0.02%	753
2025 Q2	$2.49M	Buy	26,350 +14,017	+114%	+$1.04M	﹤0.01%	1462
2025 Q1	$783K	Sell	12,333 -16,284	-57%	-$974K	﹤0.01%	1886
2024 Q4	$1.33M	Buy	28,617 +15,805	+123%	+$593K	﹤0.01%	1600
2024 Q3	$369K	Sell	12,812 -688	-5%	-$16.9K	﹤0.01%	2052
2024 Q2	$195K	Buy	+13,500	New	+$197K	﹤0.01%	2305
2024 Q1	–	Sell	-40,215	Closed	-$799K	–	2837
2023 Q4	$799K	Buy	40,215 +24,731	+160%	+$365K	﹤0.01%	1553
2023 Q3	$252K	Sell	15,484 -51,424	-77%	-$990K	﹤0.01%	1933
2023 Q2	$1.41M	Buy	+66,908	New	+$1.43M	﹤0.01%	1577
2022 Q1	–	Sell	-12,263	Closed	-$82K	–	4071
2021 Q4	$82K	Buy	+12,263	New	+$62.6K	﹤0.01%	3433

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Marshall Wace's VRNA Position: Q4 2025 in Review

Marshall Wace sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 147,768 shares — an estimated $15.8M sold.

Marshall Wace first reported a position in VRNA in Q4 2021 and held it in 10 quarters. The position peaked at $15.8M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Marshall Wace reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Marshall Wace sold 147,768 Verona Pharma shares in Q4 2025, an estimated $15.8M.
Marshall Wace first reported a position in Verona Pharma in Q4 2021 and held it in 10 quarters.
Marshall Wace's Verona Pharma position peaked at $15.8M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.